Agent handling

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Tuesday, April 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

Retrieved on: 
Friday, March 22, 2024
Urinary tract infection, Anaphylaxis, Bronchitis, European Commission, Tendon rupture, Patient, European Medicines Agency, Bempedoic acid, Ezetimibe, Therapy, Citrate synthase, Anemia, Pain, Sinusitis, Abdominal pain, Risk, Gout, Ageing, Committee, ACL, Spasm, EMA, Back pain, ATP, Safety, Fatigue, CHMP, Arthralgia, Angioedema, Tablet, Constipation, Agent handling, Death, Pregnancy, CLEAR, Rash, Kidney, Moyamoya disease, Rupture, Apolipoprotein, Hypercholesterolemia, Hypersensitivity, Health, CVD, Incidence, Diarrhea, Fetus, Esperion Therapeutics, Diet, Upper respiratory tract infection, FDC, Uric acid

ANN ARBOR, Mich. and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions for the label update of both bempedoic acid (marketed as NILEMDO®▼) and the bempedoic acid / ezetimibe fixed dose combination (FDC) (marketed as NUSTENDI®▼ ), recommending their approval as treatments to reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.2 The existing label of bempedoic acid (NILEMDO®▼) provides authorisation for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2

Key Points: 
  • “We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bempedoic acid global franchise brings to patients worldwide,” said Sheldon Koenig, President and CEO, Esperion.
  • The CHMP is a scientific committee of the EMA that reviews medical product applications on their scientific and clinical merit.
  • Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels which may lead to gout.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular events

Retrieved on: 
Friday, March 22, 2024
Health, Biometrics, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Hypercholesterolemia, European Commission, Bempedoic acid, Risk, Patient, Tablet, Committee, ACL, Ageing, Agent handling, Esperion Therapeutics, EMA, Death, European Medicines Agency, Ezetimibe, Therapy, Moyamoya disease, ATP, FDC, CHMP, Apolipoprotein, Pharmaceutical industry

“The positive CHMP opinion is a crucial milestone towards improved treatment outcomes, as we are now able to address even better the unmet needs of cardiovascular care and prevention among patients in Europe.

Key Points: 
  • “The positive CHMP opinion is a crucial milestone towards improved treatment outcomes, as we are now able to address even better the unmet needs of cardiovascular care and prevention among patients in Europe.
  • This first-in-class medicine with proven efficacy in reducing hypercholesterolaemia and preventing cardiovascular risks, is a testament to our tireless efforts to help improve the cardiovascular treatment landscape.
  • The CHMP is a scientific committee of the EMA that reviews medical product applications on their scientific and clinical merit.
  • The European Commission will review the CHMP opinions and is expected to deliver its final decision in the mid of the year 2024.

ICUS Endorses Expanded Role of Sonographers in CEUS Procedures

Retrieved on: 
Thursday, March 21, 2024
Other Health, Other Science, Pharmaceutical, Other Technology, Research, Oncology, Medical Devices, Hospitals, Genetics, Stem Cells, Science, Technology, Nursing, Cardiology, General Health, Biotechnology, Health, Health Technology, Diagnosis, Radiation, Brain, Organization, Contrast-enhanced ultrasound, UEA, IPhone, Thomas Jefferson University, CEUS, Diagnostic medical sonography, SDMS, Risk, Patient, ICUS, Echocardiography, Society, GE HealthCare, CME, Scope of practice, Google Images, Agent handling, Kidney, Definity, Android, Accreditation, Medical imaging

More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).

Key Points: 
  • More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).
  • “Sonographers play a vital role in conducting CEUS examinations, and continually learning new techniques, such as CEUS, is a core component of providing innovative care and elevating our profession,” said Maria Stanczak, a member of the ICUS board of directors who played a key role in updating CEUS content in the new Scope of Practice.
  • ICUS does not charge fees for membership, CME-accredited webinars on CEUS, newsletters and other CEUS resources or programming.
  • To join ICUS, register and learn more, visit the ICUS website at www.ICUS-Society.org , or download the free ICUS app for iPhone and Android devices.

United States Cancer Contrast Media (Gadolinium, Iodinated) Market Size, Share & Trends Analysis Report 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Oncology, Diagnosis, Breast cancer, Gadolinium, Medicine, MRI, Growth, Prevalence, Agent handling, Patient, Public, Private sector, GE HealthCare, Google Images, Lung cancer, Investment, Smoking, Contrast (vision), Air pollution, USD, Government, Iodine, Medical imaging

The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. cancer contrast media market is anticipated to reach USD 1.53 billion by 2030 and is anticipated to expand at a CAGR of 11.7% from 2024 to 2030.
  • Thus, these factors collectively propel the growth of U.S. cancer contrast media market.
  • Iodinated contrast media dominated the type segment with a share of 39.5% in 2023 owing to the increasing medical imaging procedures.

China Medical University Hospital Develops "AISIA" to Diagnose Acute Ischemic Stroke in 90 Seconds to Assist Doctors in Making Medical Decisions

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, Control, Stroke, Blood pressure, Speech, Brain, Pneumonia, Brain ischemia, Kidney, NCCT, Physician, Paralysis, Risk, External carotid artery, Patient, Contrast-induced nephropathy, Cerebrovascular disease, Mortality, Long-term care, Death, Judgement, Deep learning, Nausea, Atherosclerosis, Bleeding, Heart, Neurology, Agent handling, Ministry, Shadow, CTP, Vomiting, Artificial intelligence, Rehabilitation, Dysarthria

The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.

Key Points: 
  • The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.
  • This assist physicians in making decision of acute ischemic stroke management.
  • This system can determine the presence of acute ischemic stroke in approximately 90 seconds.
  • In this way, the facilitated AISIA platform means a lot for ischemic stroke patients and medical experts as well.

Clinical Research on Photon-Counting CT Begins with Radboud University Medical Center

Retrieved on: 
Tuesday, February 27, 2024
Photon, Perfusion, European Congress of Radiology, Canon Medical Systems Corporation, University Medical Center, European, X-ray, ECR, Agent handling, Radboud University Medical Center, Radboud University Nijmegen, Health, Teaching, Congress, Research, Medical imaging

Otawara, Japan, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) has completed the second installation of its Canon photon-counting CT (PCCT) system worldwide at Radboud University Medical Center (Chair: Dr. Bertine Lahuis; location: Nijmegen, the Netherlands), and clinical research began in late January.

Key Points: 
  • Otawara, Japan, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) has completed the second installation of its Canon photon-counting CT (PCCT) system worldwide at Radboud University Medical Center (Chair: Dr. Bertine Lahuis; location: Nijmegen, the Netherlands), and clinical research began in late January.
  • PCCT is expected to be the next generation of X-ray CT
    Radboud University Medical Center is an academic medical center specializing in patient care, scientific research, teaching, and training.
  • The Department of Radiology at Radboud University Medical Center leads one of the best research groups in Europe, working with more than 150 researchers on advanced studies to provide patient care and improve health care.
  • Canon Medical entered into an agreement on joint clinical research with Radboud University Medical Center on November 14, 2023,*1 and clinical research aimed at early practical application of PCCT was started, led by Prof. Mathias Prokop, Chairman of the Department of Radiology at Radboud University Medical Center.

Blank Rome Adds Leading White Collar Team, Continuing Nationwide Expansion

Retrieved on: 
Monday, February 26, 2024
Virginia School for Girls, Private practice, International Bar Association, Agent handling, Growth, Commerce, University, Organization, Justice minister, LL.B, Investigation, International business, Security (finance), Department of the Treasury, Settlement, Blank Rome, International, Knowledge, Economic law, Aviation, Blank, International Centre, Georgetown University Law Center, World Bank Group, Foreign Sovereign Immunities Act, Cryptocurrency

The group’s arrival continues the strategic expansion of Blank Rome’s White Collar Defense and Investigations group.

Key Points: 
  • The group’s arrival continues the strategic expansion of Blank Rome’s White Collar Defense and Investigations group.
  • In January, five white collar attorneys from litigation boutique Spears & Imes joined Blank Rome in New York, including partners David Spears , Linda Imes , and Chris Dysard .
  • In November 2023, Barrett R. Howell joined the White Collar Defense and Investigations group as a partner in the firm’s recently opened Dallas office.
  • They focus on white collar defense litigation, government investigations and enforcement actions, international disputes and arbitration, internal investigations, and advising clients on compliance programs, voluntary disclosures, and remediation.

VoIP Testing with SIP Emulation and Conformance Test Suite

Retrieved on: 
Monday, February 26, 2024
Phonation, ISUP, C'mon You Know, UAC, Command-line interface, Air traffic control, Register, ETSI, Equipment, Interactive voice response, UAS, FAX, Java, EUROCAE, Air navigation service provider, Emergency service, Instant, Human, Python, IVR, RTP, Instant messaging, SIP, DTMF, Session Initiation Protocol, Voice over IP, IP, Agent handling, Telecommunications, MSRP, ADHD (Joyner Lucas album), Telecom, Software, CPS, Mobile phone

Vijay Kulkarni, CEO of GL Communications, highlights the software's capabilities, stating, “ MAPS™ SIP is a complete VoIP emulation solution.

Key Points: 
  • Vijay Kulkarni, CEO of GL Communications, highlights the software's capabilities, stating, “ MAPS™ SIP is a complete VoIP emulation solution.
  • SIP Protocol Conformance Testing: GL's SIP testing tool boasts proficiency in emulating diverse interfaces within SIP networks, encompassing standard SIP, SIP-I (ISUP) , SIP IMS , and SIP MSRP.
  • Furthermore, it executes SIP Protocol Conformance Testing for varied SIP protocol implementations crucial to the Next Generation Air Traffic Control System , such as ED-137 compliance.
  • MAPS™ SIP Conformance Suite offers 400+ test cases aligned with ETSI TS 102 027-2 V3.1.1 (2004-11) SIP specifications.

Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award

Retrieved on: 
Wednesday, February 28, 2024
LRA, Engineering, Chronic kidney disease, LMTA, Immune system, Infection, Thrombus, Inflammation, Physician, Kidney disease, Quality of life, Lupus Research Alliance, Colchicine, Lupus, Nephritis, NETS, CD19, Skin, Cell, UV, Risk, Autoantibody, APS, Bacteria, Death, Agent handling, Mortal Kombat, Fibrosis, Clinical trial, Gene, Survival, Disease, Antiphospholipid syndrome, Kidney, SLE, S100A4, Research, DNA, Kidney failure, Vaccine

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).
  • The development of targeted treatments is hindered by an incomplete understanding of lupus and its devastating complications.
  • These seven talented investigators will identify targets for new treatments and test novel therapeutic avenues to revolutionize the field and improve the lives of individuals with lupus.
  • Surgical biopsies of the kidneys are often needed to diagnose lupus nephritis (LN), kidney inflammation caused by lupus that can result in severe and sometimes life-threatening organ damage.